1150 related articles for article (PubMed ID: 28131992)
21. H3K9 Trimethylation Silences Fas Expression To Confer Colon Carcinoma Immune Escape and 5-Fluorouracil Chemoresistance.
Paschall AV; Yang D; Lu C; Choi JH; Li X; Liu F; Figueroa M; Oberlies NH; Pearce C; Bollag WB; Nayak-Kapoor A; Liu K
J Immunol; 2015 Aug; 195(4):1868-82. PubMed ID: 26136424
[TBL] [Abstract][Full Text] [Related]
22. miR-194-5p down-regulates tumor cell PD-L1 expression and promotes anti-tumor immunity in pancreatic cancer.
Wang C; Li X; Zhang L; Chen Y; Dong R; Zhang J; Zhao J; Guo X; Yang G; Li Y; Gu C; Xi Q; Zhang R
Int Immunopharmacol; 2021 Aug; 97():107822. PubMed ID: 34098485
[TBL] [Abstract][Full Text] [Related]
23. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.
Ai L; Xu A; Xu J
Adv Exp Med Biol; 2020; 1248():33-59. PubMed ID: 32185706
[TBL] [Abstract][Full Text] [Related]
24. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.
Imai D; Yoshizumi T; Okano S; Uchiyama H; Ikegami T; Harimoto N; Itoh S; Soejima Y; Aishima S; Oda Y; Maehara Y
Cancer Med; 2017 Jul; 6(7):1614-1626. PubMed ID: 28602029
[TBL] [Abstract][Full Text] [Related]
25. MLL3 enhances the transcription of PD-L1 and regulates anti-tumor immunity.
Xiong W; Deng H; Huang C; Zen C; Jian C; Ye K; Zhong Z; Zhao X; Zhu L
Biochim Biophys Acta Mol Basis Dis; 2019 Feb; 1865(2):454-463. PubMed ID: 30385408
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma.
Yokoyama S; Miyoshi H; Nakashima K; Shimono J; Hashiguchi T; Mitsuoka M; Takamori S; Akagi Y; Ohshima K
Clin Cancer Res; 2016 Sep; 22(18):4727-34. PubMed ID: 27166394
[TBL] [Abstract][Full Text] [Related]
27. miR-193a targets MLL1 mRNA and drastically decreases MLL1 protein production: Ectopic expression of the miRNA aberrantly lowers H3K4me3 content of the chromatin and hampers cell proliferation and viability.
Sengupta D; Deb M; Kar S; Parbin S; Pradhan N; Patra SK
Gene; 2019 Jul; 705():22-35. PubMed ID: 31005612
[TBL] [Abstract][Full Text] [Related]
28. Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma.
Daunke T; Beckinger S; Rahn S; Krüger S; Heckl S; Schäfer H; Wesch D; Pilarsky C; Eckstein M; Hartmann A; Röcken C; Wandmacher AM; Sebens S
Front Immunol; 2023; 14():1157397. PubMed ID: 37449210
[TBL] [Abstract][Full Text] [Related]
29. Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer.
Fan P; Zhao J; Meng Z; Wu H; Wang B; Wu H; Jin X
J Exp Clin Cancer Res; 2019 Feb; 38(1):47. PubMed ID: 30709380
[TBL] [Abstract][Full Text] [Related]
30. ISG15 pathway knockdown reverses pancreatic cancer cell transformation and decreases murine pancreatic tumor growth via downregulation of PDL-1 expression.
Burks J; Fleury A; Livingston S; Smith JP
Cancer Immunol Immunother; 2019 Dec; 68(12):2029-2039. PubMed ID: 31709456
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
[TBL] [Abstract][Full Text] [Related]
32. Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy.
Zhai W; Zhou X; Zhai M; Li W; Ran Y; Sun Y; Du J; Zhao W; Xing L; Qi Y; Gao Y
Sci China Life Sci; 2021 Apr; 64(4):548-562. PubMed ID: 32737851
[TBL] [Abstract][Full Text] [Related]
33. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.
Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434
[TBL] [Abstract][Full Text] [Related]
34. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer.
Sasidharan Nair V; El Salhat H; Taha RZ; John A; Ali BR; Elkord E
Clin Epigenetics; 2018; 10():78. PubMed ID: 29983831
[TBL] [Abstract][Full Text] [Related]
35. Regulation of programmed death-ligand 1 expression in response to DNA damage in cancer cells: Implications for precision medicine.
Sato H; Jeggo PA; Shibata A
Cancer Sci; 2019 Nov; 110(11):3415-3423. PubMed ID: 31513320
[TBL] [Abstract][Full Text] [Related]
36. Chemokine C-C motif ligand 21 synergized with programmed death-ligand 1 blockade restrains tumor growth.
Chen Q; Yin H; Pu N; Zhang J; Zhao G; Lou W; Wu W
Cancer Sci; 2021 Nov; 112(11):4457-4469. PubMed ID: 34402138
[TBL] [Abstract][Full Text] [Related]
37. Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory.
Poggio M; Hu T; Pai CC; Chu B; Belair CD; Chang A; Montabana E; Lang UE; Fu Q; Fong L; Blelloch R
Cell; 2019 Apr; 177(2):414-427.e13. PubMed ID: 30951669
[TBL] [Abstract][Full Text] [Related]
38. Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression.
Zheng NN; Zhou M; Sun F; Huai MX; Zhang Y; Qu CY; Shen F; Xu LM
World J Gastroenterol; 2020 Jul; 26(26):3737-3749. PubMed ID: 32774054
[TBL] [Abstract][Full Text] [Related]
39. The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment.
Hudson K; Cross N; Jordan-Mahy N; Leyland R
Front Immunol; 2020; 11():568931. PubMed ID: 33193345
[TBL] [Abstract][Full Text] [Related]
40. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
